Spevigo
Spevigo ingredients
| Active ingredient | Strength |
|---|---|
| Spesolimab | 300 mg/2mL, 60 mg/mL, 150 mg/1, 300 mg/1, 150 mg/mL |
What Spevigo is used for
The FDA lists the approved uses on the official label (below). In the EU, spesolimab is approved as Spevigo for:
Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. Spevigo is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Spevigo
- Generic name
- Spesolimab
- Made by
- LEO Pharma Inc.
- Forms
- Injection
- Given
- Intravenous, Subcutaneous
- Drug class
- Interleukin-36 Receptor Antagonist
- FDA approval
- Biologic licence (BLA) BLA761244
- On the US market since
- 2022
Official information
- Spevigo prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Spesolimab)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Spevigo?
Spevigo (Spesolimab) is a specialist medicine made by LEO Pharma Inc., approved by the US FDA.
What are the ingredients of Spevigo?
Spevigo contains Spesolimab (300 mg/2mL, 60 mg/mL, 150 mg/1, 300 mg/1, 150 mg/mL).
Is Spevigo approved in Europe?
The same active substance is approved in the EU as Spevigo.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA